HUE048020T2 - Új kezelés - Google Patents

Új kezelés

Info

Publication number
HUE048020T2
HUE048020T2 HUE17174446A HUE17174446A HUE048020T2 HU E048020 T2 HUE048020 T2 HU E048020T2 HU E17174446 A HUE17174446 A HU E17174446A HU E17174446 A HUE17174446 A HU E17174446A HU E048020 T2 HUE048020 T2 HU E048020T2
Authority
HU
Hungary
Prior art keywords
new treatment
treatment
new
Prior art date
Application number
HUE17174446A
Other languages
English (en)
Inventor
Katharine Abbott-Banner
John Hanrahan
David Thomas
Original Assignee
Verona Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1408384.4A external-priority patent/GB201408384D0/en
Priority claimed from GBGB1417719.0A external-priority patent/GB201417719D0/en
Application filed by Verona Pharma Plc filed Critical Verona Pharma Plc
Publication of HUE048020T2 publication Critical patent/HUE048020T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE17174446A 2014-05-12 2015-05-11 Új kezelés HUE048020T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1408384.4A GB201408384D0 (en) 2014-05-12 2014-05-12 New treatment
GBGB1417719.0A GB201417719D0 (en) 2014-10-07 2014-10-07 New treatment

Publications (1)

Publication Number Publication Date
HUE048020T2 true HUE048020T2 (hu) 2020-05-28

Family

ID=53264683

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17174446A HUE048020T2 (hu) 2014-05-12 2015-05-11 Új kezelés

Country Status (16)

Country Link
US (2) US10864213B2 (hu)
EP (2) EP3142701B1 (hu)
AU (1) AU2015261239B2 (hu)
CA (1) CA2948620C (hu)
CY (2) CY1120550T1 (hu)
DK (2) DK3142701T3 (hu)
ES (2) ES2773142T3 (hu)
HU (1) HUE048020T2 (hu)
IL (1) IL248856B (hu)
MX (1) MX2016014756A (hu)
PL (2) PL3142701T3 (hu)
PT (2) PT3231444T (hu)
RU (1) RU2688191C2 (hu)
SI (2) SI3142701T1 (hu)
WO (1) WO2015173551A1 (hu)
ZA (1) ZA201607705B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3708564A1 (en) 2005-12-28 2020-09-16 Vertex Pharmaceuticals Incorporated A solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX342288B (es) 2010-04-22 2016-09-23 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
ES2957761T3 (es) 2014-04-15 2024-01-25 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
HUE048020T2 (hu) 2014-05-12 2020-05-28 Verona Pharma Plc Új kezelés
ES2670025T3 (es) 2014-09-15 2018-05-29 Verona Pharma Plc Formulación para inhalación líquida que comprende RPL554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
IT201700085714A1 (it) * 2017-07-26 2019-01-26 Luigi Maiuri Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
GB201911517D0 (en) * 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
US11963965B2 (en) * 2019-12-26 2024-04-23 National Jewish Health Methods of treating cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE455946B (sv) 1986-10-20 1988-08-22 Trion Forskning & Utveckling Nya pertussistoxin-polypeptider och antigener samt testsatser, vacciner och intradermala hudtestkompositioner
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
AU2178392A (en) 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
ES2099415T3 (es) 1991-12-18 1997-05-16 Minnesota Mining & Mfg Formulaciones de aerosol en suspension.
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
CN1145478C (zh) 1998-04-18 2004-04-14 葛兰素集团有限公司 药用气溶胶制剂
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
ES2208310T3 (es) 1999-03-31 2004-06-16 Vernalis Limited Derivados de pirimido(6,1-a) isoquinolin-4-ona.
ATE233084T1 (de) 1999-04-14 2003-03-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung
CA2810655C (en) 2004-06-24 2013-12-10 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
NZ609962A (en) 2008-11-06 2014-11-28 Vertex Pharma Modulators of atp-binding cassette transporters
JP2013504524A (ja) 2009-09-11 2013-02-07 シエシー ファルマセウティチィ ソシエタ ペル アチオニ イソオキサゾリジン誘導体
RU2577541C2 (ru) * 2010-08-09 2016-03-20 ВЕРОНА ФАРМА ПиЛСи КРИСТАЛЛИЧЕСКАЯ ФОРМА СОЕДИНЕНИЯ ПИРИМИДО [6, 1-а]ИЗОХИНОЛИН-4-ОНА
RU2585767C2 (ru) 2010-11-26 2016-06-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные глицина и их применение в качестве антагонистов мускариновых рецепторов
WO2012107364A1 (en) 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
EP2744493A1 (en) * 2011-08-18 2014-06-25 Shire AG Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy
CN104470518A (zh) * 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 药物组合物及其施用
CN105229547A (zh) 2013-03-14 2016-01-06 林肯环球股份有限公司 导出或者使用针对外部系统的焊接定序器数据的系统和方法
PL2968312T3 (pl) 2013-03-15 2018-08-31 Verona Pharma Plc Kombinacja leków
HUE048020T2 (hu) 2014-05-12 2020-05-28 Verona Pharma Plc Új kezelés
ES2670025T3 (es) 2014-09-15 2018-05-29 Verona Pharma Plc Formulación para inhalación líquida que comprende RPL554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
GB202002786D0 (en) 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition

Also Published As

Publication number Publication date
CY1122748T1 (el) 2021-03-12
IL248856A0 (en) 2017-01-31
IL248856B (en) 2020-07-30
AU2015261239B2 (en) 2020-02-27
ES2682105T3 (es) 2018-09-18
EP3231444A1 (en) 2017-10-18
RU2016148447A3 (hu) 2018-12-27
US11759467B2 (en) 2023-09-19
DK3231444T3 (da) 2020-03-16
WO2015173551A1 (en) 2015-11-19
PT3231444T (pt) 2020-03-05
ZA201607705B (en) 2020-05-27
SI3142701T1 (en) 2018-08-31
CA2948620C (en) 2023-01-24
US20210106585A1 (en) 2021-04-15
RU2016148447A (ru) 2018-06-19
CA2948620A1 (en) 2015-11-19
SI3231444T1 (sl) 2020-04-30
EP3142701A1 (en) 2017-03-22
US10864213B2 (en) 2020-12-15
AU2015261239A1 (en) 2016-12-01
EP3231444B1 (en) 2019-12-18
CY1120550T1 (el) 2019-07-10
DK3142701T3 (en) 2018-08-13
MX2016014756A (es) 2017-03-23
US20170112839A1 (en) 2017-04-27
RU2688191C2 (ru) 2019-05-21
PL3231444T3 (pl) 2020-05-18
PT3142701T (pt) 2018-10-18
ES2773142T3 (es) 2020-07-09
PL3142701T3 (pl) 2018-11-30
EP3142701B1 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
PT3132034T (pt) Terapêutica
IL248856A0 (en) New treatment
GB201522243D0 (en) Treatment
GB201401430D0 (en) Treatment process
GB201502137D0 (en) Treatment
GB201410216D0 (en) Therapeutic
SG11201601030VA (en) Massager
GB201406989D0 (en) Novel treatments
GB201519450D0 (en) Novel treatment
PT3099317T (pt) Tripsina de bacalhau para utilização no tratamento de infeções microbianas num indivíduo com imunodeficiência
GB201412011D0 (en) Treatments
GB201510637D0 (en) Therapeutic
GB201508841D0 (en) Treatment
GB201411027D0 (en) Treatment
GB201503008D0 (en) Treatment
GB201414542D0 (en) Novel therapy
GB201417719D0 (en) New treatment
GB201408384D0 (en) New treatment
GB201518349D0 (en) Treatment
GB201413317D0 (en) Atheroscierosis treatment
GB201515739D0 (en) Treatment
GB201412411D0 (en) Treatment
GB201412410D0 (en) Treatment
GB201514008D0 (en) Treatment
GB201400235D0 (en) Treatment